Company intelligence / Profile preview

ATI Atlas

Ownership: Private
Development stage: Other

Overview

Atlas Biotech is an early-stage biotech company specializing in functional genomics, synthetic biology, and massively multiplexed assays. Their core focus is designing and screening biological libraries (e.g., protein variants, CRISPR screens) to elucidate structure-function relationships relevant to disease. While historically focused on oncology, they are expanding into rare diseases and inflammatory disease models. The company does not appear to have clinical-stage therapeutic assets but rather provides high-quality datasets and novel assays for discovery research.

Therapeutic areas: OncologyImmunologyRare Diseases
Modalities: Synthetic biologyFunctional genomicsDeep mutational scanningCRISPR-based therapyBase editing
Industry: Non-Drug Biotech

Beyond the preview

Go deeper on ATI Atlas.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ATI Atlas.

Explore the full profile